On June 7, 2022, the Federal Trade Commission (FTC) unanimously voted to initiate a study into how business practices employed by some pharmacy benefit managers (PBMs) may impact.
The FTC issued two orders for public comment in June 2022 settling allegations that JAB Consumer Partners’ $1.1 billion acquisition of SAGE Veterinary Partners and $1.65 billion acquisition of the parent of veterinary clinic owner Ethos violated federal antitrust laws.
House passed largely along party lines a package of gun control measures advanced by the Judiciary Committee on June 2, Senate bipartisan negotiations continued on a more narrow response to gun violence that they hope can attain the 60 votes needed to surpass a filibuster.
“Although many people have never heard of pharmacy benefit managers, these powerful middlemen have enormous influence over the U.S. prescription drug system,” FTC Chair Lina M. Khan said this week.